Compounds > arginine

arginine and edoxaban

arginine has been researched along with edoxaban in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	9 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ansell, JE; Bakhru, SH; Brown, K; Costin, JC; Dishy, V; Grosso, M; Laulicht, BE; Noveck, RJ; Steiner, SS	1
Cuker, A; Siegal, D	1
Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI	1
Antman, EM; Giugliano, RP; Ruff, CT	1
Fanikos, J; Huisman, MV	1
Ansell, JE; Bakhru, SH; Brown, K; Costin, JC; Dishy, V; Grosso, MA; Lanz, HJ; Laulicht, BE; Mercuri, MF; Noveck, RJ; Steiner, SS	1
Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH	1
Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P	1
Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI	1

Reviews

7 review(s) available for arginine and edoxaban

Article	Year
Monitoring and reversal of direct oral anticoagulants. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time	2015
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American heart journal, 2016, Volume: 177 Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism	2016
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Circulation, 2016, Jul-19, Volume: 134, Issue:3 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles	2016
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. The American journal of emergency medicine, 2016, Volume: 34, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles	2016
Clinical implications of reversal agents for direct oral anticoagulants. Future cardiology, 2017, Volume: 13, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
The role of new oral anticoagulants in orthopaedics: an update of recent evidence. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2017, Volume: 27, Issue:5 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thrombosis and haemostasis, 2019, Volume: 119, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin	2019

Trials

1 trial(s) available for arginine and edoxaban

Article	Year
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thrombosis and haemostasis, 2017, 01-26, Volume: 117, Issue:2 Topics: Administration, Oral; Adult; Arginine; Blood Coagulation; Double-Blind Method; Drug Monitoring; Factor Xa Inhibitors; Humans; Injections, Intravenous; Male; North Carolina; Piperazines; Pyridines; Thiazoles; Whole Blood Coagulation Time	2017

Other Studies

1 other study(ies) available for arginine and edoxaban

Article	Year
Use of PER977 to reverse the anticoagulant effect of edoxaban. The New England journal of medicine, 2014, Nov-27, Volume: 371, Issue:22 Topics: Arginine; Blood Coagulation; Factor Xa Inhibitors; Heparin Antagonists; Humans; Piperazines; Pyridines; Thiazoles	2014